📣 VC round data is live. Check it out!
- Public Comps
- Bioporto
Bioporto Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioporto and similar public comparables like Eurofins-Cerep, Agfa-Gevaert, Allianca Saude, MDxHealth and more.
Bioporto Overview
About Bioporto
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.
Founded
2000
HQ

Employees
31
Website
Financials (LTM)
EV
$83M
Valuation Multiples
Start free trialBioporto Financials
Bioporto reported last 12-month revenue of $6M and negative EBITDA of ($12M).
In the same LTM period, Bioporto generated $5M in gross profit, ($12M) in EBITDA losses, and had net loss of ($9M).
Revenue (LTM)
Bioporto P&L
In the most recent fiscal year, Bioporto reported revenue of $6M and EBITDA of ($13M).
Bioporto is unprofitable as of last fiscal year, with gross margin of 75%, EBITDA margin of (205%), and net margin of (201%).
Financial data powered by Morningstar, Inc.
Bioporto Stock Performance
Bioporto has current market cap of $91M, and enterprise value of $83M.
Market Cap Evolution
Bioporto's stock price is $0.18.
Bioporto share price increased by 3.8% in the last 30 days, and decreased by 15.8% in the last year.
Bioporto has an EPS (earnings per share) of $-0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $83M | $91M | 0.2% | 3.8% | 28.3% | -15.8% | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioporto Valuation Multiples
Bioporto trades at 13.2x EV/Revenue multiple, and (7.1x) EV/EBITDA.
EV / Revenue (LTM)
Bioporto Financial Valuation Multiples
As of May 8, 2026, Bioporto has market cap of $91M and EV of $83M.
Bioporto has a P/E ratio of (10.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioporto Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bioporto Margins & Growth Rates
Bioporto grew revenue by 5% but EBITDA decreased by 26% in the last fiscal year.
In the most recent fiscal year, Bioporto reported gross margin of 75%, EBITDA margin of (205%), and net margin of (201%).
Bioporto Margins
Bioporto Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bioporto Operational KPIs
Bioporto's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.
Bioporto's Rule of 40 is (141%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioporto's Rule of X is (134%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Bioporto Competitors
Bioporto competitors include Eurofins-Cerep, Agfa-Gevaert, Allianca Saude, MDxHealth, FluoGuide, Curasight, Exagen, Klea, Aiforia and Cyclopharm.
Most Bioporto public comparables operate across Medical Imaging & Diagnostics and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.4x | — | 9.1x | — | |||
| 0.1x | 0.1x | 2.6x | 2.6x | |||
| 0.8x | — | 5.6x | — | |||
| 1.5x | 1.4x | (124.1x) | 220.4x | |||
| — | — | (10.8x) | (9.9x) | |||
| — | — | (11.9x) | (10.9x) | |||
| 1.0x | 1.0x | (6.9x) | (7.6x) | |||
| 3.4x | — | 15.3x | — | |||
This data is available for Pro users. Sign up to see all Bioporto competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioporto
| When was Bioporto founded? | Bioporto was founded in 2000. |
| Where is Bioporto headquartered? | Bioporto is headquartered in Denmark. |
| How many employees does Bioporto have? | As of today, Bioporto has over 31 employees. |
| Is Bioporto publicly listed? | Yes, Bioporto is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Bioporto? | Bioporto trades under BIOPOR ticker. |
| When did Bioporto go public? | Bioporto went public in 1993. |
| Who are competitors of Bioporto? | Bioporto main competitors include Eurofins-Cerep, Agfa-Gevaert, Allianca Saude, MDxHealth, FluoGuide, Curasight, Exagen, Klea, Aiforia, Cyclopharm. |
| What is the current market cap of Bioporto? | Bioporto's current market cap is $91M. |
| What is the current revenue of Bioporto? | Bioporto's last 12 months revenue is $6M. |
| What is the current revenue growth of Bioporto? | Bioporto revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Bioporto? | Current revenue multiple of Bioporto is 13.2x. |
| Is Bioporto profitable? | No, Bioporto is not profitable. |
| What is the current EBITDA of Bioporto? | Bioporto has negative EBITDA and is not profitable. |
| What is Bioporto's EBITDA margin? | Bioporto's last 12 months EBITDA margin is (186%). |
| What is the current EV/EBITDA multiple of Bioporto? | Current EBITDA multiple of Bioporto is (7.1x). |
| What is the current FCF of Bioporto? | Bioporto's last 12 months FCF is ($8M). |
| What is Bioporto's FCF margin? | Bioporto's last 12 months FCF margin is (122%). |
| What is the current EV/FCF multiple of Bioporto? | Current FCF multiple of Bioporto is (10.8x). |
| How many companies Bioporto has acquired to date? | Bioporto hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Bioporto has invested to date? | Bioporto hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Bioporto
Lists including Bioporto
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.